SITC Pre-Conference on November 8, 2017

Immuno-Oncology Biomarkers: Today's Imperatives for Tomorrow's Needs

Panel Discussion

Challenge: Improvement of cancer immunotherapies by developing analytically-validated, standardized assays/tools for measuring mechanistically-informative biomarkers that can undergo clinical validation in NCI-supported clinical trials

Opportunity: Establishment of a Network of Cancer Immune Monitoring and Analysis Centers (CIMACs) & Cancer Immunologic Data Commons (CIDC) funded by the Cancer Moonshot Program

NIH NATIONAL CANCER INSTITUTE

Minkyung (Min) Song, Magdalena Thurin, Helen Chen, Malcolm Smith, David Patton, Yingdong Zhao, and **Jeffrey Abrams**

CIMACs-CIDC Network

Purpose

To serve as the infrastructure for correlative studies in NCI-supported clinical trials involving cancer immunotherapy

Goal

To identify immune and tumor marker candidates with a translational potential for optimizing therapeutic strategies for cancer patients

Assays available at CIMACs

Enable comprehensive analyses of diverse variables, including genomic, phenotypical and immunological correlates, by employing standardized platforms as well as novel assays to be developed within the Network

Proposed Structure of the CIMACs-CIDC Network



- Each CIMAC is led by a **multidisciplinary team** (experts in assays, statistical/computational experts, translational scientists, clinicians).
- Each CIMAC will be aligned with **Clinical Trials Networks, Consortia, and other NCI-supported clinical trials** to **collaborate in scientific planning, tissue accession, data analysis, and publication**.
- A given CIMAC may perform all or specific assays for each study, depending on resource prioritization and expertise.
- Utilization of the CIMACs-CIDC resource is **voluntary**, but the studies will **require collaboration with the CIMACs investigators and approval from the Cancer Therapy Evaluation Program (CTEP) in NCI**.